These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22269183)

  • 1. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
    Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
    BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
    BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
    Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
    AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
    Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
    J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
    Gallant JE; Moore RD
    AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
    Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
    J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing recovery of renal function after tenofovir disoproxil fumarate discontinuation.
    Yoshino M; Yagura H; Kushida H; Yonemoto H; Bando H; Ogawa Y; Yajima K; Kasai D; Taniguchi T; Watanabe D; Nishida Y; Kuwahara T; Uehira T; Shirasaka T
    J Infect Chemother; 2012 Apr; 18(2):169-74. PubMed ID: 21968965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215).
    De Beaudrap P; Diallo MB; Landman R; Guèye NF; Ndiaye I; Diouf A; Kane CT; Etard JF; Girard PM; Sow PS; Delaporte E;
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1221-7. PubMed ID: 20854202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
    Viganò A; Bedogni G; Manfredini V; Giacomet V; Cerini C; di Nello F; Penagini F; Caprio C; Zuccotti GV
    Clin Drug Investig; 2011; 31(6):407-15. PubMed ID: 21528939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.
    Gupta SK; Anderson AM; Ebrahimi R; Fralich T; Graham H; Scharen-Guivel V; Flaherty JF; Fortin C; Kalayjian RC; Rachlis A; Wyatt CM
    PLoS One; 2014; 9(3):e92717. PubMed ID: 24651857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.
    Pujari SN; Smith C; Makane A; Youle M; Johnson M; Bele V; Joshi K; Dabhade D; Bhagani S
    BMC Infect Dis; 2014 Mar; 14():173. PubMed ID: 24679159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
    Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
    Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.